ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Panel Member at Inflammasome Therapeutics Summit 2021

Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to share information and address knowledge gaps in this rapidly evolving field

ZyVersa is well positioned in the emerging inflammasome space with a highly differentiated inflammasome ASC inhibitor (IC 100), which has potential to treat a broad range of inflammatory diseases

News provided by

ZyVersa Therapeutics, Inc.

Sep 09, 2021, 07:08 ET

WESTON, Fla., Sept. 9, 2021 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa's Co-Founder, Chief Executive Officer, and Chairman, is an invited panel member at the Inflammasome Therapeutics Summit 2021. The virtual conference is being held November 16-18, 2021.  

Continue Reading
Stephen C. Glover Co-Founder, Chief Executive Officer, and Chairman, ZyVersa Therapeutics
Stephen C. Glover Co-Founder, Chief Executive Officer, and Chairman, ZyVersa Therapeutics

Mr. Glover and the other panel members, Paul Ashton, President & CEO of Inflammasome Therapeutics, and Anil K. Goyal, CEO & Chairperson of IMMvention Therapeutix, will address thought-provoking topics including:

  • Key learnings from recent progress and failures
  • Drivers of inflammasome therapeutics development
  • Market opportunity and untapped clinical areas
  • Bottlenecks in inflammasome therapeutics clinical success

The panel discussion will take place:

Date: Wednesday, November 17th
Time: 9:00-9:30 am ET
Event Registration Link: Inflammasome Therapeutics Summit 2021

To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, please request a one-on-one virtual meeting.

About ZyVersa Therapeutics, Inc.

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our development pipeline includes a novel inflammasome inhibitor with potential to treat multiple inflammatory diseases, and phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of a rare kidney disease, focal segmental glomerulosclerosis (FSGS), with potential to treat other kidney diseases. For more information, please visit www.zyversa.com.

SOURCE ZyVersa Therapeutics, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED